Working with Industry
Basic page
The ECMCs play a leading role in speeding up the process of cancer treatment development and the search for prognostic, predictive and pharmacological cancer biomarkers that help move towards personal treatment. In 2014/15, over 153 companies conducted trials through the ECMC Network, and of the early phase trials supported by...
About us
Basic page
Our Vision Through collaboration and teamwork, the ECMC network aims to ... Enhance the delivery of early phase trials by providing capacity, increasing speed and efficiency, and ensuring safety Ensure that the UK remains at the forefront of international efforts to develop and test new treatments for cancer, built upon...
ECMC Programme Office
Basic page
ECMCs
Basic page
The foundation of each ECMC is a partnership between the local NHS Trust and the University, bringing together university-based health researchers with hospital based clinical staff and researchers. How ECMCs contribute to the cancer research pathway
Patients and Public
Basic page
Patient Participation: The development of new and improved treatments cannot be achieved without patients willing to participate in studies, by agreeing to try experimental treatments and providing samples of their cancer for further testing. However, due to the nature of ECMC trials, not every patient is able to take part...
Capability, capacity, portfolio
Basic page
Diverse Capabilities Biologicals Cell therapies Immunotherapies Small molecules DNA damage repair Epigenetics Growth factors Tumour microenvironment Combinations Mechanisms of resistance Rational scientific design Translational Animal models Biomarker expertise Stratified medicine Imaging Regulatory requirements Validated assays Tissue sampling GCP PK/PD lab sampling Capacity of the Network Since 2007, the ECMC infrastructure...
Interview: Guy Makin, Paediatric Network
Interview
The ECMC Paediatric Network brings together clinicians and translational scientists to run early phase clinical trials in children and young people with cancer across 12 centres in the UK.. Dr Guy Makin, ECMC Paediatric Network Lead, talks about the challenges and opportunities for early phase paediatric research. Why did you...
Industry case studies
Case Study
ATLANTIS trial Barts-Brighton ECMC has formed a partneship around the ATLANTIS trial, a personalised therapy study in bladder cancer. In partnership with Exelixis and Astellas, BARTS ECMC will run the translational oncology biomarker part of the study, supported by a grant of £550,000. TORC 1 & 2 in breast cancer...
Interview: Clinical trials patient, Lyn Barrington
Interview
Theatre nurse, Lyn Barrington, also a former colorectal nurse specialist, describes her experiences of being diagnosed with lung cancer and of her journey to being accepted on an immunotherapy trial. With many thanks to Lyn for all her time, commitment and honesty. It took two years for your cancer to...